Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Implantable 3D Patch Closes and Repairs Heart Defects

By HospiMedica International staff writers
Posted on 12 Aug 2025

Following a heart attack, reduced blood flow deprives the heart of oxygen, leading to tissue damage. More...

In severe cases, the heart wall can rupture, requiring immediate surgical repair. Current treatment involves bovine pericardial patches, which are stable and permeable but remain foreign bodies and can trigger calcification, thrombosis, or inflammation. Now, a 3D-printed cardiac patch can match the mechanical properties of the heart and withstand internal blood pressure, thereby closing defects as well as helping damaged heart tissue regenerate.

An interdisciplinary research team from ETH Zurich (Zurich, Switzerland) and the University Hospital of Zurich (Zurich, Switzerland) has developed the “RCPatch” (Reinforced Cardiac Patch) for intraventricular implantation. The device, presented in the study in Advanced Materials, combines a fine mesh to seal damage, a 3D-printed degradable polymer scaffold for stability, and a hydrogel enriched with living heart muscle cells. This three-part design allows the patch to integrate into existing heart tissue and degrade naturally once healing is complete.

The lattice-structured scaffold is printed from a degradable polymer, providing enough strength to withstand cardiac pressures. The mesh component, infused with a hydrogel containing living cells, facilitates attachment to the heart and promotes tissue growth. By combining these components, the RCPatch creates a dense yet flexible structure that enables biological integration rather than permanent implantation of inert material.

In an initial animal experiment, the patch was successfully implanted and withstood high pressure, preventing bleeding and restoring cardiac function. The researchers then conducted preclinical tests on pig models, using the RCPatch to close artificial defects in the left ventricle. These tests showed the patch maintained structural integrity under real blood pressure.

These findings establish a promising basis for a mechanically reinforced, tissue-engineered heart patch suitable for human implantation. Long-term, the aim is for the device to not only repair but also regenerate myocardial tissue. Future work will focus on improving material properties and assessing stability in extended animal studies before moving toward clinical use.

Related Links:
ETH Zurich
University Hospital of Zurich


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Mobile X-Ray System
K4W
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The 3D-printed microneedle patch boosts live-virus vaccine delivery (Photo courtesy of IIS/University of Tokyo)

3D-Printed Delivery System Enhances Vaccine Delivery Via Microneedle Array Patch

The COVID-19 pandemic underscored the need for efficient, durable, and widely accessible vaccines. Conventional vaccination requires trained personnel and cold-chain logistics, which can slow mass immunization... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.